Moniyot-131 Τ Για Θεραπευτική Χρήση (Sodium Iodide (131i))

Sodium Iodide-131 is taken up by thyroid cells through the sodium‑iodide symporter. Inside the cell, the isotope emits beta radiation that destroys the cell’s DNA, leading to selective removal of hyperfunctioning or malignant thyroid tissue without affecting most other body tissues.

The dose of Moniyot-131 is individualized and determined by the prescribing physician based on the specific indication, disease severity, and patient characteristics. No standard dose is provided here; clinicians calculate the activity required for each case.

Moniyot-131 is generally contraindicated in pregnancy because the radiation can affect the developing fetus. Breastfeeding is also discouraged, as the drug may be secreted in breast milk. Use only if the potential benefit outweighs the risk and after thorough risk assessment.

To order Moniyot-131, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with surgical removal or antithyroid drugs, Moniyot-131 offers a non‑invasive option that selectively targets thyroid tissue. It avoids the risks of anesthesia and surgery, but requires careful dosing and monitoring for radiation‑related effects. Choice of therapy depends on disease stage, patient preference and clinical guidelines.

Moniyot-131 should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight and physical damage. Follow all local regulations for handling radiopharmaceuticals, and ensure that only authorized personnel manage the material.

Moniyot-131 is administered orally as a single dose, usually in capsule or liquid form, under the supervision of a qualified healthcare professional. Patients may be instructed to avoid certain foods or medications before and after dosing to optimize thyroid uptake.

Serious risks include severe bone marrow suppression, which can lead to pancytopenia, radiation‑induced thyroiditis, and the rare possibility of secondary malignancies. Patients should be monitored closely for blood count changes and any signs of acute inflammation after treatment.

Moniyot-131 should not be used in patients who are pregnant, breastfeeding, have severe renal impairment, or have a known hypersensitivity to iodine or radiopharmaceuticals. Additionally, individuals with uncontrolled thyroid disorders that require immediate surgical intervention may be unsuitable candidates.